Physician profile
George Bone
NPI 1528028297
$2,181.21
in general payments reported to CMS, 2019-2025
21 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $37.63 · 2021: $210 · 2022: $413 · 2023: $336 · 2024: $620 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $399.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $325.57 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $264.51 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $205.49 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $205.13 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $159.97 | 2022-2025 | |
| Abbott Laboratories | $101.21 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $92.02 | 2022 | |
| Novartis Pharmaceuticals Corporation | $69.71 | 2021-2023 | |
| Pfizer INC. | $64.93 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $42.80 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $36.85 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.18 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $28.29 | 2025 | Korlym |
| Arbor Pharmaceuticals, INC. | $28.22 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $28.12 | 2024 | Sovuna |
| Exact Sciences Corporation | $25.45 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $21.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.04 | 2021 | |
| Amgen INC. | $17.09 | 2025 | Repatha |
| Allergan, INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.